These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35243292)

  • 1. Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches.
    Paredes AJ; Volpe-Zanutto F; Vora LK; Tekko IA; Permana AD; Picco CJ; McCarthy HO; Donnelly RF
    Mater Today Bio; 2022 Jan; 13():100217. PubMed ID: 35243292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis.
    Zhang C; Wu Y; Hutton ARJ; Hidayat Bin Sabri A; Hobson JJ; Savage AC; McCarthy HO; Paredes AJ; Owen A; Rannard SP; Donnelly RF
    Int J Pharm; 2024 Jul; 660():124317. PubMed ID: 38851410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride.
    Paredes AJ; Volpe-Zanutto F; Permana AD; Murphy AJ; Picco CJ; Vora LK; Coulter JA; Donnelly RF
    Int J Pharm; 2021 Sep; 606():120885. PubMed ID: 34271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV.
    Puri A; Bhattaccharjee SA; Zhang W; Clark M; Singh O; Doncel GF; Banga AK
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30970630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).
    Johnson LM; Krovi SA; Li L; Girouard N; Demkovich ZR; Myers D; Creelman B; van der Straten A
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31277461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
    Jiang Y; Gao X; Singh ON; Zhang W; Agrahari V; Peet MM; Clark MR; Doncel GF; Banga AK
    Int J Pharm; 2020 May; 582():119342. PubMed ID: 32315746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
    Chua CYX; Jain P; Ballerini A; Bruno G; Hood RL; Gupte M; Gao S; Di Trani N; Susnjar A; Shelton K; Bushman LR; Folci M; Filgueira CS; Marzinke MA; Anderson PL; Hu M; Nehete P; Arduino RC; Sastry JK; Grattoni A
    J Control Release; 2018 Sep; 286():315-325. PubMed ID: 30092254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.
    Simpson SM; Widanapathirana L; Su JT; Sung S; Watrous D; Qiu J; Pearson E; Evanoff A; Karunakaran D; Chacon JE; Kiser PF
    Pharm Res; 2020 Apr; 37(4):83. PubMed ID: 32296951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections.
    Peng K; Vora LK; Tekko IA; Permana AD; Domínguez-Robles J; Ramadon D; Chambers P; McCarthy HO; Larrañeta E; Donnelly RF
    J Control Release; 2021 Nov; 339():361-380. PubMed ID: 34619227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microneedle array patches for sustained delivery of fluphenazine: A micron scale approach for the management of schizophrenia.
    Abu Ershaid JM; Vora LK; Volpe-Zanutto F; Sabri AH; Peng K; Anjani QK; McKenna PE; Ripolin A; Larrañeta E; McCarthy HO; Donnelly RF
    Biomater Adv; 2023 Oct; 153():213526. PubMed ID: 37348183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
    J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrogel-forming microneedles for rapid and efficient skin deposition of controlled release tip-implants.
    Peng K; Vora LK; Domínguez-Robles J; Naser YA; Li M; Larrañeta E; Donnelly RF
    Mater Sci Eng C Mater Biol Appl; 2021 Aug; 127():112226. PubMed ID: 34225871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling HIV Pre-Exposure Prophylaxis.
    Straubinger T; Kay K; Bies R
    Front Pharmacol; 2019; 10():1514. PubMed ID: 32082142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
    Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
    Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.